Methods of making chemokine alpha 3 antibodies

Details Methods of making chemokine alpha 3 antibodies Methods of making chemokine alpha 3 antibodies

2004-09-08

2008-09-02

Saoud, Christine (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S139100, C530S387900

Reexamination Certificate

active

07419662

ABSTRACT:
Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

REFERENCES:
patent: 4897348 (1990-01-01), Johnson et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5278287 (1994-01-01), Rollins et al.
patent: 5306709 (1994-04-01), Gewirtz
patent: 5346686 (1994-09-01), Lyle et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5401651 (1995-03-01), Walz
patent: 5504003 (1996-04-01), Li et al.
patent: 5525486 (1996-06-01), Honjo et al.
patent: 5605817 (1997-02-01), Coleman et al.
patent: 5633149 (1997-05-01), Guegler et al.
patent: 5871723 (1999-02-01), Streiter et al.
patent: 6372456 (2002-04-01), Wei et al.
patent: 0 488 900 (1992-06-01), None
patent: 0 679 716 (1995-11-01), None
patent: WO 91/04274 (1991-04-01), None
patent: WO 92/06196 (1992-04-01), None
patent: WO 94/12537 (1994-06-01), None
patent: WO 96/17868 (1996-06-01), None
patent: WO 96/22374 (1996-07-01), None
patent: WO 96/24668 (1996-08-01), None
patent: WO 97/35027 (1997-09-01), None
patent: WO 98/11227 (1998-03-01), None
Orfanoudakis et al. Bacterially expressed Fabs of monoclonal antibodies neutralizing tumour necrosis factor alpha in vitro retain full binding and biological activity. Mol Immunol 30(16): 1519-1528, 1983.
Hoogenboom et al. Building antibodies from their genes. Immunolog Rev 130:41-68, 1992.
Singh, S. Protein engineering of antibodies. Crit Rev Biotechnol 12: 437-462, 1992.
Supplementary Partial European Search Report, Application No. 96911336.4, dated Oct. 14, 2004.
Chang et al. “Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene”, J. Biol. Chem. 269(41):25277-25282 1994.
Baggiolini, M. et al., “Human Chemokines: An Update,”Annu. Rev. Immunol. 15:675-705 (Apr. 1997).
Bischoff, S.C. et al., “Monocyte Chemotactic Protein 1 Is a Potent Activator of Human Basophils,”J. Exp. Med. 175(5):1271-1275 (1992).
Blum, S. et al., “Three Human Homologs of a Murine Gene Encoding an Inhibitor of Stem Cell Proliferation,”DNA and Cell Biology9(8):589-602 (1990).
Brown, K.D. et al. “A Family of Small Inducible Proteins Secreted by Leukocytes are Members of a New Superfamily that Includes Leukocyte and Fibroblast-Derived Inflammatory Agents, Growth Factors, and Indicators of Various Activation Processes,”J. Immunol. 142(2):679-687 (1989).
“Chemokines,” inR&D Systems 1995 Catalog, R&D Systems, Minneapolis, MN (Nov./Dec. 1994, pp. 80-85.
Clark-Lewis, I. et al., “Structure-activity relationships of chemokines,”J. Leukoc. Biol. 57:703-711 (May 1995).
Colditz, I. et al., “In Vivo Inflammatory Activity of Neurotrophil-Activating Factor, a Novel Chemotactic Peptide Derived from Human Monocytes,”Am. J. Pathol. 134(4):755-760 (1989).
Derynck, R., et al., “Recombinant Expression, Biochemical Characterization, and Biological Activities of the Human MGSA/groProtein,”Biochemistry29(44):10225-10233 (1990).
Gong, J.H. et al., “Rantes and MCP-3 Antagonists Bind Multiple Chomokine Receptors,”J. Biol. Chem. 271(18):10521-10527 (May 1996).
Goodman, R.B. et al., “Molecular Cloning of Porcine Alveolar Macrophage-Derived Meutrophil Chemotactic Factors I and II: Identification of Porcine IL-8 and Another Intercrine-α Protein,”Biochemistry31(43):10483-10490 (1992).
Gress, T.M. et al., “Hybridization fingerprinting of high-density cDNA-Library arrays with cDNA pools derived from whole tissues,”Mamm. Gen. 3(11):609-619 (1992).
Hara, T. et al, “Molecular Cloning and Functional Characterization of a Novel Member of the C-C Chemokine Family,”J. Immunol. 155(11):5352-5358 (Dec. 1995).
Horuk, R. et al., “The Duffy antigen receptor for chemokines: structural analysis and expression in the brain,”J. Leukoc. Biol. 59(1):29-38 (Jan. 1996).
Howard, O.M.Z. et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents,”Tibtech14(2):46-51 (Feb. 1996).
Jose, P.J. et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation,”J. Exp. Med. 179(3):881-887 (1994).
Kuna, P. et al., “Monocyte Chemotactic and Activating Factor is a Potent Histamine-releasing Factor for Human Basophils,”J. Exp. Med. 175:489-493 ((1992).
Kurdowska, A. et al., “Biological and Kinetic Characterization of Recombinant Human Macrophage Inflammatory Peptides 2 Alpha and Beta and Comparison with the Neutrophil Activating Peptide 2 and Interleukin 8,”Cytokine6(2):124-134 (1994).
Kwon, D. and Weissman, S.M., “cDNA sequences of two inducible T-cell genes,”PNAS USA86:1963:1967 (1989).
Liao, F. et al., “Human Mig Chemokine: Biochemical and Functional Characterization,”J. Exp. Med. 182(5):1301-1314 (Nov. 1995).
Lukacs, N.W. et al., “The Role of Macrophage Inflammatory Protein 1 α inSchistosoma mansoniEgg-induced Granulomatous Inflammation,”J. Exp. Med. 177:1551-1559 (1993).
Luo, Y. et al., Biologic Activities of the Murine β-Chemokine TCA3,J. Immunol. 153(10):4616-4624 (1994).
Matsushima, K. et al., “Purification and Characterization of a Novel Monocyte Chemotactic and Activating Factor Produced by a Human Myelomonocytic Cell Line,”J. Exp. Med. 169:1485-1490 (1989).
Matsushima, K. et al., “Molecular Cloning of a Human Monocyte-Derived Neutrophil Chemotactic Factor (MDNCF) and the Induction of MDNCF mRNA by Interleukin 1 and Tumor Necrosis Factor,”J. Exp. Med. 167:1883-1893 (1988).
Nakao, M. et al., “Structures of Human Genes Coding for Cytokine LD78 and Their Expression,”Mol. Cell. Biol. 10(7):3646-3658 (1990).
Obaru, K. et al., “A cDNA Clone Used to Study mRNA Inducible in Human Tonsillar Lymphocytes by a Tumor Promoter,”J. Biochem. 99(3):885-894 (1986).
Proost, P. et al., “Human and Bovine Granulocyte Chemotactic Protein-2: Complete Amino Acid Sequence and Functional Characterization as Chemokines,”Biochemistry32(38):10170-10177 (1993).
Proudfoot, A.E.I. et al., “Extension of Recombinant Human Rantes by the Retention of the Initiating Methionine Produces a Potent Antagonist,”J. Biol. Chem. 271(5):2599-2603 (Feb. 1996).
Schall, T.J. et al., “Biology of the Rantes/Sis Cytokine Family,”Cytokine3(3):165-183 (1991).
Schulz-Knappe, P. et al., “HCC-1, a Novel Chemokine from Human Plasma,”J. Exp. Med. 183(1):295-299 (Jan. 1996).
Sudo, K., et al., “2058 Expressed Sequence Tags (ESTs) from a Human Fetal Lung cDNA Library,”Genomics24:276-279 (1994).
Szabo, M.C. et al., “Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor,”J. Biol. Chem. 270(43):25348-25351 (Oct. 1995).
Taub, D.D. and Oppenheim, J.J. et al., “Chemokines, inflammation and the immune system,”Ther. Immunol. 1:229-246 (1994).
Wells, T.N.C. et al., “Selectivity and antagonism of chemokine receptors,”J. Leukoc. Biol59(1)

Affiliated with

Also associated with

Rating

Methods of making chemokine alpha 3 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of making chemokine alpha 3 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of making chemokine alpha 3 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3981131